T A B L E O F C O N T E N

Main results
We identified 18 randomized trials (4723 participants). Pooled estimates showed significant reductions in both thromboembolic events (RR 0.50, 95% CI 0.36 to 0.69) and all-cause mortality (RR 0.64, 95% CI 0.46 to 0.89). This reduction in mortality remained significant after the removal of low-quality studies (RR 0.65, 95% CI 0.46 to 0.90). Trials of self-management alone showed significant reductions in thromboembolic events (RR 0.47, 95% CI 0.31 to 0.70) and all-cause mortality (RR 0.55, 95% CI 0.36 to 0.84); selfmonitoring did not (thrombotic events RR 0.57, 95% CI 0.32 to 1.00; mortality RR 0.84, 95% CI 0.50 to 1.41). Self-monitoring significantly reduced major haemorrhages (RR 0.56, 95% CI 0.35 to 0.91) whilst self-management did not (RR 1.12, 95% CI 0.78 to 1.61). Twelve trials reported improvements in the percentage of mean INR measurements in the therapeutic range. No heterogeneity was identified in any of these comparisons.
Authors' conclusions
Compared to standard monitoring, patients who self-monitor or self-manage can improve the quality of their oral anticoagulation therapy. The number of thromboembolic events and mortality were decreased without increases in harms. However, self-monitoring or self-management were not feasible for up to half of the patients requiring anticoagulant therapy. Reasons included patient refusal, exclusion by their general practitioner, and inability to complete training.
P L A I N L A N G U A G E S U M M A R Y
Self-monitoring and self-management of oral anticoagulation therapy
Near patient or point-of-care testing devices have made it possible for people on long-term oral anticoagulation to monitor their blood clotting time measured as the international normalized ration (INR) in the home setting. Patients who self-test can either adjust their medication dose according to a pre-determined dose-INR schedule (self-management) or they can call a clinic to be told the appropriate dose adjustment (self-monitoring). Several published studies suggest these methods of monitoring anticoagulation therapy may be equal to or better than standard monitoring by a physician.
In total, we found 18 randomized trials that compared self-monitoring and self-management with standard monitoring. The combined results of these trials showed a halving of thromboembolic events and all-cause mortality with self-monitoring and self-management and no reduction in the number of major bleeds. Self-management had similar reductions in thromboembolic events and mortality to the overall benefit, with no effect on major bleeds. Self-monitoring halved the number of major haemorrhages that occurred but did not significantly reduce the rates of thrombotic events or all-cause mortality.
In conclusion, self-monitoring or self-management can improve the quality of oral anticoagulant therapy, leading to fewer thromboembolic events and lower mortality, without a reduction in the number of major bleeds. Self-monitoring and self-management are not feasible for all patients, which requires the identification and education of suitable patients.
B A C K G R O U N D
Oral anticoagulation therapy with vitamin K antagonists has been shown to reduce thromboembolic events (Connolly 1991; Corporative 1990; SPAF 1996; EAFT 1993; Ezekowitz 1992; Go 2003) in multiple clinical contexts. These include atrial fibrillation, treatment of deep-vein thrombosis, prosthetic heart valves, and acute myocardial infarction. Optimal anticoagulation with warfarin or other vitamin k antagonists like acenocumarole or phenprocoumon could potentially prevent more than half of the strokes related to atrial fibrillation and heart valve replacements with a relatively low risk of major bleeding complications (Buckingham 2002) ; however, much of this potential is still not obtained because of under and suboptimal use (Stafford 1998).
The number of patients receiving oral anticoagulant drugs has been constantly increasing during the last decade. Reasons include improvements in clinical outcomes, increasing common disease indications for their use (Manotti 2001) , and improvements in anticoagulant safety (Ansell 2001) . In 1994, 250,000 patients in the United Kingdom were receiving anticoagulant therapy (Baglin 1994) ; 10 years later this number had increased to around 950,000 patients (Fitzmaurice 2005) . Vitamin k antagonist (warfarin, acenocumarole, or phenprocoumon) treatment usually requires regular monitoring of prothrombin time (PT) with dose-adjustment by a specialized hospital service, primary care physician, registered nurse, nurse practitioner, or pharmacist (Hirsh 1998).
Numerous obstacles to the use of warfarin exist; including practical, patient, physician, and healthcare system-related barriers. Due to the complex pharmacokinetics of warfarin, continuous monitoring and dose adjustments are required. Different values and preferences amongst physicians and patients about the relative importance of bleeding and thromboembolic events, non-adherence to drug treatment, non-adherence to clinical guidelines, drug interactions, and increased costs of monitoring and therapy all have significant roles to play in the management of anticoagulation therapy (Heneghan 2008).
Vitamin k antagonists belong to the drug class known as coumarins. They produce their anticoagulant effect by interfering with the metabolism of vitamin k. There are various different types of coumarins but warfarin is the most prescribed drug. Warfarin has a high bioavailability (Breckenridge 1978) and is rapidly absorbed from the gastrointestinal tract so that maximal blood concentrations are reached 90 minutes after oral administration. Warfarin has a half-life of 36 to 42 hours; in the blood it is bound to plasma proteins (mainly albumin). It accumulates in the liver where the two isomers are metabolically transformed by different pathways (Ansell 2004) . Another vitamin K antagonist is acenocumarole, which has a similar action to warfarin but differs in some pharmacological properties (for example it has a shorter half life and a lower risk of haemorrhage). The maximum activity of both drugs is reached within one or two days of treatment and the anticoagulant effect is maintained for approximately two days after stopping treatment with acenocumarole and between two and five days with warfarin. Phenprocoumon is another vitamin k antagonist that has traditionally been the oral anticoagulant of choice in Europe. It has similar actions to other vitamin k antagonists but has a half-life of 144 hours. As a result of their pharmacokinetic properties, these agents interact with many other drugs and their blood levels are affected by vitamin k intake in the diet, changes in metabolism, and concomitant illnesses, which makes the levels difficult to control (Greenblatt 2005) .
The pharmacodynamics of warfarin are subject to genetic and environmental variability (Hirsh 2001) such that there is considerable variation in the action of these drugs both between different individuals (inter-individually) and within the same individual (intra-individually). A 'therapeutic target range' has been established to deal with this variability and is expressed as the international normalized ratio (INR). This INR was established as a standard way of reporting the prothrombin time (PT). Furthermore, using the INR formula (INR = patient PT/mean normal PT) the ratio between patient PT and normal PT is calculated to the power of the ISI (International Sensitivity Index), which is the conversion factor for the used thromboplastin against the WHO standard.
The 'therapeutic range' for anticoagulants is narrow. INR values over 4.5 increase the risk of major bleeding and an INR less than 2 increases the risk of thromboembolism (Cannegieter 1995; Hylek 1996; Kearon 2003) . The inter and intra-individual variability and the narrow target range requires frequent testing and appropriate adjustment of the drug dose. In addition, time within the therapeutic INR target range is highly dependent on the frequency of testing (Horstkotte 1998) . Different values and preferences amongst patients and physicians have also been described with the former willing to accept a much higher risk of bleeding for an associated reduction in risk of stroke (Devereaux 2001 ).
An economic model analysed the cost of suboptimal oral anticoagulation and showed the following. If 50% of those not receiving warfarin prophylaxis had optimal anticoagulation, 19,380 emboli would be prevented and 1.1 billion US dollars could be saved. If 50% of those currently receiving warfarin as part of routine medical care had optimal anticoagulation, 9852 emboli would be prevented and 1.3 billion US dollars could be saved (Caro 2004 ).
Current models of oral anticoagulation management within the UK include the traditional hospital outpatient model and various forms of community-based models, all requiring patient attendance at a clinic (Fitzmaurice 2002) . In other countries, such as Canada, a primary care physician monitors the INR and adjusts the warfarin dose (Sunderji 2004).
The introduction of portable monitors (point-of-care devices) allows the patient to self-test at home with a drop of whole blood. Portable monitors for monitoring long-term oral anticoagulation were introduced in the 1990s. Portable monitors have proved to be reliable with regard to analytical accuracy, although INR measurements tend to be lower with the portable coagulometers compared to laboratory analysers (Christensen 2009; Poller 2006) .
Generally patients receive a structured educational programme given by the nurses or physicians responsible for their care. In addition, they receive training in self-testing, instructions to prevent bleeding and thromboembolic complications, and are made aware of the effects of diet and medications. Patients who self-test can either adjust their therapy according to a pre-determined dose-INR schedule (self-management) or they can call a clinic to be told the appropriate dose adjustment (self-monitoring).
In some countries, such as Germany, self-monitoring and selfmanagement with portable monitors are established therapeutic methods. There are several available point-of-care devices and the most well known is the CoaguChek® monitor. Other available monitors are the ProTime® Microcoagulation System, INRatio® Monitor, Hemochron Junior Signature, and the TAS near-patient test system. Potential advantages of self-monitoring and self-man-agement include improved convenience for patients, better treatment adherence, more frequent monitoring, and fewer thromboembolic and haemorrhagic complications (Taborski 1999). Near-patient testing devices have made self-testing of anticoagulation therapy with vitamin k antagonists possible. Guidelines generally do not endorse self-monitoring or self-management (Fitzmaurice 2001) despite several authors of trials suggesting this approach may be equal to or better than standard monitoring (Anderson 1993; Cromheecke 2000; Sawicki 1999) . A recent study suggested that self-monitoring and self-management are cost-effective strategies for those receiving long-term oral anticoagulation (Regier 2006).
To establish the strength of the available evidence, we conducted a systematic review of the impact of patient self-monitoring or selfmanagement on treatment with oral anticoagulation therapy.
Terminology
• Point-of-care testing (POC): diagnostic testing performed in a clinic, home, or other site of patient care (rather than in standard reference laboratory)
• Point-of-care device: portable monitor used by a healthcare provider (physician, nurse, or other) or patient to determine a clinical measure
• Self-monitoring: the trained patient uses point-of-care testing to perform the INR test and inform his or her healthcare provider of the result. The physician or another healthcare provider adjusts the anticoagulant dose using the results obtained by the patient
• Self-management: trained patient uses point-of-care testing to perform the INR test, interpret the result, and adjust the dosage of anticoagulant accordingly (adapted from Brown 2007)
O B J E C T I V E S
To evaluate the effects on thrombotic events, major haemorrhages, and all-cause mortality of self-monitoring or self-management of oral anticoagulation compared to standard monitoring.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomized controlled trials (RCTs) assessing the therapeutic effectiveness and safety of self-monitoring or self-management of oral anticoagulation therapy.
Types of participants
All patients, adults and children, on long-term anticoagulant therapy (treatment duration longer than two months) irrespective of the indication for treatment (for example valve replacement, venous thromboembolism, atrial fibrillation).
Types of interventions
Self-monitoring or self-management of oral anticoagulation as compared to:
1. control of and dosage by personal physician; 2. anticoagulation managed services (hospital anticoagulation service); 3. anticoagulation clinics (management conducted by registered nurses, nurse practitioners, or pharmacists using dosage-adjustment protocols).
Types of outcome measures
Primary outcome measures
• Thromboembolic events • Mortality from all causes • Major haemorrhage (e.g. haemorrhage requiring hospital admission or transfusion)
• Time in range, and proportion of measurements within the therapeutic range for each particular condition
Secondary outcomes
• Minor haemorrhage (e.g. bleeding after minor trauma, nose bleed)
• Frequency of testing • Feasibility of testing: patient factors (e.g. physical limitations), and non-patient factors (e.g. inability to attend training)
• Quality of life and general satisfaction with treatment
Search methods for identification of studies Electronic searches
We searched We limited our searches to randomized controlled trials by using a maximally sensitive strategy adapted to each database (Dickersin 1994; Lefebvre 1996) . The full search strategies are available in Appendix 1.
Searching other resources
We searched for ongoing trials (for example on the UK National Research Register, Trials Central, Current Controlled Trials) and handsearched reference lists of all retrieved papers. We contacted Roche ® Diagnostics (one manufacturer of PT and INR monitors) in order to identify further published and unpublished studies. There were no language restrictions.
Data collection and analysis
Data extraction
Two review authors (JM, PA) screened studies for inclusion and retrieved all potentially relevant studies. Three review authors (JM, PA, CH) independently extracted data on study population, intervention, pre-specified outcomes, methodology, and quality from eligible trials. The review authors were not blinded to any aspect of the studies (for example journal type, authors' names, institution). We resolved disagreements by consensus. If needed, we sought additional information from authors. We used Cohen's kappa to assess agreement between the two review authors on the selection of articles for inclusion. We extracted information on disease characteristics and training provided to the different groups. In the self-management group we extracted information on the actions patients subsequently undertook. We extracted the characteristics of the population studied, including the number of and reasons for participants not entering the trial (for example refusal or exclusion). Additionally, we sought information on the reasons for discontinuation by participants allocated to the intervention. In the case of cross-over studies, the outcomes of interest are potentially confounded by the cross-over and we only used data from the first part of the trial (before cross-over).
Quality assessment
Three review authors (JM, PA, CH) independently extracted methodological information for the assessment of internal validity. They used the following five components: method of randomization, concealment of allocation, intention to treat, number of and reasons for patient losses to follow up, and blinding. We did a sensitivity analyses for study quality by including only those studies with clear methods of randomization and concealment of allocation (high quality studies). We also used GRADE to assess the quality of the included studies.
Quantitative data synthesis
For the analysis we used Review Manager (RevMan) Version 5.0.
For the statistical analysis we calculated relative risks (RRs) and 95% confidence intervals (CIs) as summary statistics. We used a fixed-effect model with the Mantzel-Haenzel method to calculate the pooled odds ratio; and Peto's method to verify the results in uncommon outcomes. We examined heterogeneity amongst studies with the Chi 2 and I 2 statistics (Higgins 2003). Where significant heterogeneity existed we used the random-effects model (DerSimonian 1986). We examined publication bias by constructing a funnel plot of precision (SE of the log RR) against RR for the endpoints of major haemorrhage and thromboembolic episodes. We performed a sensitivity analysis by excluding low quality studies and pre-specified subgroup analyses according to clinical indication (mechanical valve replacement or atrial fibrillation), and self-monitoring or self-management therapy. We performed a post-hoc subgroup analysis according to who provided the control group care (specialist anticoagulation clinic, family physician). Meta-regression in STATA tested any subgroup interaction on the outcomes. The ratio of the average test frequency per individual patient/year between intervention and control groups was calculated and linear regression was used to assess the association with study duration. Pooling of the mean percentage of tests in the therapeutic range was not possible; results were summarized using means and ranges. We tested subgroup interactions using meta-regression (Intercooled STATA 9.1 for Windows).
To provide further insight into the adequacy of the total sample size across all trials we calculated a posteriori the optimal information needed for our meta-analysis (Pogue 1997). To determine this optimal information size we assumed a 2% risk of thromboembolism (median control event rate from trials in the review) and a 50% RR reduction with a power of 95% and a two-sided alpha = 0.01.
R E S U L T S Description of studies
See: Characteristics of included studies; Characteristics of excluded studies; Characteristics of ongoing studies. We identified 463 citations of which 123 duplicate records were excluded, leaving 340 potentially relevant studies. We independently reviewed 41 retrieved articles for inclusion and data extraction. One additional unpublished trial was included after the initial screen (Kaatz Unpublished). Two review authors achieved good agreement in the initial selection of trial titles for inclusion (kappa 0.72, 95% CI 0.59 to 0.86) and on the inclusion of full-text articles (kappa 0.81, 95% CI 0.62 to 1.01).
A total of 18 trials that compared self-monitoring or self-management of oral anticoagulation to standard monitoring met the eligibility criteria (Figure 1 ). These trials were published between 1989 and 2007 and were largely undertaken in Europe (five in UK; four in Germany; two in Netherlands; one in each of Spain, Denmark, and Austria); five were undertaken in United States and Canada. In total, 4723 participants on long-term anticoagulation were included in our analysis. All studies but one (Cromheecke 2000) used a cross-over design. We located one unpublished study and were given access to the complete data by the authors (Kaatz Unpublished). 
Risk of bias in included studies
The reported quality was generally moderate. We contacted nine authors of the 18 included trials for additional details of randomisation process, concealment of allocation, and blinding. The additional information provided generally raised our ratings of the quality of the trial, indicating that authors had met methodological criteria. We also obtained valuable validity information from the ACP Journal Club structured reviews on two occasions. ACP reviews contact study authors when needed and are a valuable source of additional information for validity issues.
After the addition of extra information supplied by authors, four trials were judged to be of poor quality (Gardiner 2005; Khan 2004; Sidhu 2001; White 1989) and were removed in the sensitivity analysis. These four trials did not perform intention-totreat analyses and allocation concealment was unclear. According to GRADE (Figure 4 ) the available evidence was judged to be moderate due to flaws in study design; most commonly there was an absence of information about the allocation concealment procedure or blinding and the number of events was less than 300 for the primary outcomes (Characteristics of included studies). 
Follow up
Of those assigned to the intervention, 25% (range 0% to 57%) stopped self-monitoring or self-management by the end of the trial. Eight trials used an intention-to-treat analysis ( Table 1 ). Of that population, 7974 were either excluded or decided not to take part. The average proportion of people that could not (or would not) take part in the trials was 68% (range 31% to 88%). In trials which included older populations (Beyth 2000; Fitzmaurice 2005) the exclusion rates were much higher.
Secondary endpoints
Minor haemorrhage
Of the patients assigned to the intervention 24.9% (range 0% to 57.3%) were unable to complete self-monitoring or self-management. The main reasons for the drop-outs were: problems with the device, physical limitations preventing self-testing and problems with attending the training assessments or failing the assessment.
Other outcomes
Eight studies evaluated quality of life outcomes. 
Optimal information size
The calculated optimal information size needed for a reliable and conclusive treatment effect was 5150 in each arm. This assumed a 2% thromboembolic event rate in the control group, a 50% RR reduction, a power of 95%, and a two-sided alpha = 0.01. The current meta-analysis has just over 2300 in each arm, which would give a 60% power using the same assumptions. One of the main trials included in the meta-analysis showed a clear absence of correlation between the benefits observed and the degree of control (Menendez-Jandula 2005). We therefore questioned the influence of this study by performing a post hoc sensitivity analysis that removed the trial; the beneficial effects observed for all the major outcomes remained similar.
D I S C U S S I O N
To our knowledge the present study is the most comprehensive review to date. The analysis provides new information in terms of individual outcomes and the limitations of self-monitoring or selfmanagement. Our results need to be treated with some caution. Although self-monitoring or self-management of oral anticoagulation leads to a significant 50% reduction in thromboembolism and 13% reduction in major haemorrhage, the 36% reduction in mortality from all causes was largely influenced by one study. In those who used self-management therapy there appeared to be a greater reduction in thromboembolic events and mortality than with self-monitoring alone, but at a cost of less reduction in major haemorrhage. In addition, the applicability of self-monitoring and self-management is low and reluctance of suitable patients to participate in the trials was high.
This systematic review provides information additional to that in previously published reviews of self-monitoring or self-man- The results are broadly similar as this review showed significant reductions in thromboembolic events (odds ratio (OR) 045, 95% CI 030 to 068), all-cause mortality (OR 061, 038 to 098), and major haemorrhage (OR 065, 042 to 099). Trials of combined self-monitoring and selfmanagement showed significant reductions in thromboembolic events (OR 027, 012 to 059) and death (OR 037, 016 to 085) but not major haemorrhage effects (OR 093, 042 to 205).
That patients who are capable of self-management therapy have fewer thromboembolic events and lower mortality at the expense of no reduction in major haemorrhage events compared with those who self-monitor alone is of interest. It would seem that patients who self-manage may deem a major haemorrhage less detrimental than a thrombotic event. This may occur if clinicians are more reluctant to risk a haemorrhagic event at the expense of a concommitant increase in thrombotic events. This explanation is hypothetical and can only be explored through the capture of individual patient data.
Intrinsic limitations to self-monitoring and self-management include the reluctance of individuals to participate in self-management and the extensive training required to do so. Self-monitoring is not feasible for up to half of the patients requiring anticoagulation. Factors influencing patient participation within trials included problems with the device; physical limitations; attending training sessions; or failing the assessment. An additional problem with adoption in clinical practice will be the relatively high cost of the test strips. The reliability of self-testing devices can affect test results; however, available devices give INR results which are comparable with those obtained in laboratory testing (Ansell 2005). Self-monitoring and self-management is also associated with a rate of testing that is higher than with usual care. In effect self-managed warfarin dosing is analogous to self-adjusted insulin dosing according to a pre-specified sliding scale (Ansell 1996) . Such selfmanaged treatment has been practiced for years by people with diabeties (Ansell 1996) and the use of self-monitoring or self-management offers independence and freedom to travel for selected patients.
Our review has some potential limitations. First, our search was comprehensive making serious publication bias less likely but it remains a concern. Therefore the results may represent an overestimate of the true effect of treatment. Second, variability in the quality of care in the control groups can affect the rate of testing and hence the benefit and safety of standard anticoagulation monitoring. Specialist programmes may improve outcomes by the same mechanism as self-monitoring or self-management, that is improving the time in therapeutic range and lessening the frequency of adverse outcomes. However, our post hoc subgroup analysis did not verify this effect. A further modifying factor is education and training. The two trials in which patients consented to participate and received education alone had better results than did those patients allocated to routine care (Gadisseur 2003 Self mge; Gadisseur 2003 Self monit; Khan 2004). Third, for all the major outcomes of this review, limitations in the published reports led to an absence of information about the allocation concealment procedure or blinding. However, several authors were successfully contacted and the additional information that they provided generally raised the assessed quality of the trials. This finding is in agreement with recent empirical evidence suggesting that authors fail to report concealment of randomisation and blinding (Devereaux 2004). The limitations outlined above weaken the reported inferences concerning the effects of self-monitoring or self-management and led us to rate the quality of the evidence as moderate (GRADE 2008) . Fourth, it was not possible to combine the proportion of tests in range nor determine the mean time in range and the rate of outlier values. To further understand the effects of self-monitoring and self-management on both the time in range and tests in range an individual patient data meta-analysis is required. Only one trial had a duration of over two years, though long-term benefits for self-management have been seen in a nonrandomized study over five years (Sawicki 2003) . Fifth, we applied the logic of early stopping of randomized controlled trials to determine whether our meta-analysis could be considered definitive (Montori 2005) . From this we determined whether the evidence is adequate to recommend that no further studies are needed (Pogue 1997). The calculated optimal information size needed to reliably detect a plausible treatment effect was larger than the one we achieved (5150 versus 2300 patients per group).
Self-monitoring and self-management are likely to prevent thromboembolism to a greater extent than with standard monitoring. The mechanism of effect is probably through increasing the number of INR values in range and therefore the longer time that patients are in the therapeutic range. The observed reduction in mortality is likely to be related to the lower incidence of fatal thromboembolic events. Despite the limitations outlined above the apparent beneficial effects are large, and even smaller true underlying effects would probably justify widespread use of self-monitoring and self-management of oral anticoagulation in suitable candidates. Larger, better designed trials are necessary to definitively establish the magnitude of effect of this strategy; population-based observational studies can reflect real clinical practice.
and the true extent of the observed effect. Further studies should explore components of the intervention that affect the feasibility of self-monitoring and self-management and identify means to improve uptake and effectiveness. Self-monitoring or self-management is potentially not feasible for half of the patients requiring anticoagulation. The costs of meters and test strips may prevent wide-scale uptake in low and middle income countries, where this intervention could have considerable benefit.
Implications for research
The moderate quality of the evidence, potential for biases, and the fact that the optimal information size has not been achieved means that there is a need for a large, pragmatic multicentre trial. Such trials should account for the potential confounding effects of education and the quality of the control group care. We are aware of a large study in the US which is due to be published in 2010 (Matchar 2005) . We will update this review once the results from this study are published. To further explore important subgroup effects, we are undertaking an individual patient data meta-analysis of the identified studies. The results from this analysis will be available in 2010. In addition, for the results to be generalisable to the population at large, there is a need for population-based studies that collect data on adverse event rates, time in range, and factors that impinge on successful self-monitoring and self-management. The nature of this intervention lends itself to a registry to guarantee its safety and effectiveness in clinical practice. Future studies should set out to understand why people decide to use selfmanagement (or not) and should incorporate consumer knowledge about self-management, triggers to seek care, self-efficacy or self-confidence to self-manage, and perceived or actual support.
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R E F E R E N C E S C H A R A C T E R I S T I C S O F S T U D I E S Characteristics of included studies [ordered by study ID]
Beyth 2000
Methods Multicentre randomized controlled trial. Randomization was stratified according to baseline risk.
Participants
The study enrolled 325 hospitalized patients, mean age 75 years, who were receiving intravenous heparin every 24 hours. The study was based in several university hospitals (Cleveland).
Interventions
Self-monitoring
The intervention group (n=163) used home self-testing using Coumatrak Protime Test System ® to self-monitor prothrombin time. 1-hour education session, patients phoned results to coach who made recommendations. The conventional management group (n=162) received medical care including management, dosing and medical information managed by primary care physician as per usual care. Duration of the study 6 months. Oral anticoagulant used: warfarin.
Outcomes
Percentage time within target range. Complications including major bleeding, thromboembolic and mortality.
Notes
One to one teaching. Training lasted 30 min to 1 hour. Patients instructed to check prothrombin 3 times in the first week after hospital discharge and weekly in the first month, and monthly thereafter depending on the results. 100% up at 6 months.
Risk of bias
Item
Authors' judgement Description
Adequate sequence generation? Unclear Randomization stated to have been done but no method reported.
Allocation concealment? Yes Clearly adequate concealment.
Intention to treat analysis? Yes
Reporting of losses of follow-up? Unclear <20% losses to follow up.
Blinding? Yes Blinded data collectors.
Christensen 2006
Methods Single centre randomized controlled trial.
Participants
The study enrolled 100 ambulatory patients. Mean age 63 years intervention group mean age 69 years control group. Oral anticoagulation therapy for at least 8 months. The study was based in
the Center of Self-managed Oral Anticoagulation (Denmark).
Interventions
Self-management
The intervention group (n=50) receive self-management using Coaguchek ® to measure INR once a week and these results were used by the patient to adjust the coumarin dosage. The conventional management group (n=50) received at least monthly blood sampling either at the hospital laboratory nearest the patient's home or with a coagulometer at a physician's office. These results were used to adjust the coumarin dosage. Duration of the study 6 months. Oral anticoagulant used: coumarin.
Outcomes
Major bleeding. 
Notes
No formal training. The patient assumed gradually management and self adjustment with monitoring. After 27 weeks there was a formal examination.
Risk of bias
Item
Authors' judgement Description
Adequate sequence generation? Yes Computerized randomization schedule.
Allocation concealment? Yes
Intention to treat analysis? Yes
Reporting of losses of follow-up? Yes 10% of patients were lost to follow up.
Cromheecke 2000
Methods Single centre randomized controlled crossover trial. Allocation concealment by sealed envelopes. No washout period.
Participants
The study enrolled 50 consecutive outpatients, mean age 42 years, who were receiving long-term anticoagulation (phenprocoumon or acenocumarol). The study was based in the departments of cardiology and internal medicine of the Academic Medical Centre (Amsterdam).
Interventions
Self-management
The intervention group used home self-testing using Coaguchek ® to self-monitor prothrombin time and self-dosing testing performed once a week. The conventional management was done by the anticoagulation clinic. After three months patients crossed over the alternative management strategy. Duration of the study 3 months. Oral anticoagulant used: acenocoumarol 65% patients, phenprocoumon 35% patients. 
Notes
All patients were educated and trained to self-manage anticoagulation during a structured educational program of two 2 hours sessions. None (0%) losses to follow up. 
Risk of bias
Fitzmaurice 2002
Methods Multicentre randomized controlled trial. Randomization by computer generated coding.
Participants
The study enrolled 56 ambulatory patients (most receiving warfarin for atrial fibrillation). Mean age 63 years self-management mean age 69 years control group. The study was based in six general practices in the west Midlands using the Birmingham model of anticoagulation management.
Interventions
Self-management
The intervention group (n=30) used self-testing and self-dosing using Coaguchek ® device to selfmonitor INR. Testing was performed every 2 weeks or after 1 week following dosage adjustment. Conventional management group (n=26) received routine care in practice clinics. Follow up six months. Duration of the study 6 months. Oral anticoagulant used: warfarin.
Outcomes
Haemorrhage (minor and serious adverse events). Quality of life. Percentage of time in range. Proportion of time in range. Cost analysis.
Notes
Intervention group atended two 1-2 hours workshops. Workshops were based within individual practices, were organised by research staff and attended by practice staff. 
Risk of bias
Item
Authors' judgement Description
Adequate sequence generation? Yes Centralized telephone randomization.
Allocation concealment? Yes The sequence of randomization was concealed until the patient was assigned to a group.
Intention to treat analysis? Yes
Reporting of losses of follow-up? Unclear 11.9% of patients were lost to follow-up.
Blinding? Yes Blinded outcome assessors.
Sawicki 1999
Methods Multicentre randomized study.
Participants
The study enrolled 179 patients, mean age 55 years, receiving long term oral anticoagulation. The study was based in 5 referral centres (Germany).
Interventions
Self-management
The intervention group (n=90) used home self-testing and self-dosing the Coagucheck 
Risk of bias
Item
Authors' judgement Description
Adequate sequence generation? Yes Computer program.
Siebenhofer 2007
Methods Multicentre randomized controlled trial.
Participants
The study enrolled 195 patients, mean age 69 years, with indication of long term oral anticoagulation. The study was based in 3 departments specializing in the treatment of patients receiving long-term oral anticoagulation therapy (Austria).
Interventions
Self-management
The intervention group (n=99) received home self-testing using the Coagucheck ® and self-dosing. INR testing performed once a week, adjust anticoagulant dosage accordingly, and to contact the training centre in case of difficulties. 
Notes
Patients assigned to the control group participated in a single 90-miute session including basic theoretical information. Patients assigned to intervention group participated in four consecutive weekly instruction sessions of 90 to 120 minutes each, in groups of three to six patients.
Risk of bias
Item
Authors' judgement Description
Adequate sequence generation? Yes Computer-based system.
Allocation concealment? Yes Allocation was done by a central statistical office by fax and without awareness of subject data. The sequence of randomisation was concealed until the patient was assigned to a group.
Intention to treat analysis? Yes
Reporting of losses of follow-up? Yes
Sunderji 2004
Participants
The study enrolled 139 patients, mean age 60 years, receiving warfarin for at least one month before randomization. Selected patients for study inclusion based on their assessment of competency, compliance and willingness to manage their own therapy. Based in a tertiary care setting or by referral as an outpatient at the University of British Colombia (Canada).
Sunderji 2004 (Continued) Interventions
Self-management
The intervention group (n=69) received home self-testing using Protime microcoagulation system and self-dosing determining the appropriate dose of oral anticoagulant and the time of the next INR test using a nomogram recording INR results and warfarin doses in a pocket calendar. The conventional management group (n=70) used primary care physician as per usual care. Duration of the study up to 8 months. Oral anticoagulant used: warfarin.
Outcomes
Major and minor haemorrhage. Thromboembolic. Mortality. Percentage INR within target range.
Notes
In a first 2-3h visit patients received education from a pharmacist. Participants were discharged to enable practice self-testing at home. In the second visit (1-2h) patients were required to demonstrate competency in self-testing and self-dosing.
Risk of bias
Item
Authors' judgement Description
Adequate sequence generation? Yes Computer-generated randomization code.
Allocation concealment? Yes Randomization code concealed.
Intention to treat analysis? Yes
Voller 2005
Participants
The study enrolled 202 patients, mean age 64 years, with permanent non-valvular atrial fibrillation in long term anticoagulation. The study was based in 33 centres (Germany).
Interventions Self-management Self testing using the Coagucheck ® and self dosing (regime not reported 
Risk of bias
Item
Authors' judgement Description
D E C L A R A T I O N S O F I N T E R E S T
None known
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